Platelet transfusions in the neonatal intensive care unit:factors predicting which patients will require multiple transfusions

BACKGROUND: Previous studies suggest that recombinant thrombopoietin (rTPO) will increase platelet production in thrombocytopenic neonates. However, the target populations of neonates most likely to benefit should be defined. Studies suggest that rTPO will not elevate the platelet count until 5 days after the start of treatment. Therefore, the neonates who might benefit from rTPO are those who will require multiple platelet transfusions for more than 5 days. This study was designed to find means of prospectively identifying these patients.

[1]  R. Christensen,et al.  Dose–response relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non‐thrombocytopenic neonates to recombinant thrombopoietin , 2000, British journal of haematology.

[2]  A. Hutson,et al.  Pharmacokinetics, Pharmacodynamics, and Safety of Administering Pegylated Recombinant Megakaryocyte Growth and Development Factor to Newborn Rhesus Monkeys , 1999, Pediatric Research.

[3]  R. Ohno,et al.  Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis , 1999, American Journal of Gastroenterology.

[4]  I. Roberts,et al.  Thrombopoietin Has a Primary Role in the Regulation of Platelet Production in Preterm Babies , 1999, Pediatric Research.

[5]  W. Jelkmann,et al.  Expression of the thrombopoietin gene in human fetal and neonatal tissues. , 1999, Blood.

[6]  W. Jelkmann,et al.  Hepatic thrombopoietin mRNA levels in acute and chronic liver failure of childhood , 1999, Hepatology.

[7]  A. Gangl,et al.  Thrombopoietic cytokines and reversal of thrombocytopenia after liver transplantation. , 1999, European journal of gastroenterology & hepatology.

[8]  D. Calhoun,et al.  Plasma thrombopoietin concentrations in thrombocytopenic and non‐thrombocytopenic patients in a neonatal intensive care unit , 1999, British journal of haematology.

[9]  J. Dame,et al.  Thrombopoietin (Tpo) in the fetus and neonate: Tpo concentrations in preterm and term neonates, and organ distribution of Tpo and its receptor (c-mpl) during human fetal development. , 1999, Early human development.

[10]  T. Ishikawa,et al.  Reduced expression of thrombopoietin is involved in thrombocytopenia in human and rat liver cirrhosis , 1998, Journal of gastroenterology and hepatology.

[11]  D. Srivastava,et al.  A single intravenous dose of murine megakaryocyte growth and development factor potently stimulates platelet production, challenging the necessity for daily administration. , 1998, Blood.

[12]  A. Roberts,et al.  Endogenous Thrombopoietin Levels and Effect of Recombinant Human Thrombopoietin on Megakaryocyte Precursors in Term and Preterm Babies , 1998, Pediatric Research.

[13]  R. Benjamin,et al.  Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recombinant Human Thrombopoietin in Patients with Cancer , 1997, Annals of Internal Medicine.

[14]  R. Figlin,et al.  Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. , 1997, The New England journal of medicine.

[15]  B. Chong,et al.  Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. , 1997, Blood.

[16]  C. Begley,et al.  Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer , 1996, The Lancet.

[17]  S. Hanson,et al.  Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. , 1996, Blood.

[18]  S. Hanson,et al.  Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. , 1996, Blood.

[19]  K. Kier,et al.  Thrombocytopenia in Intensive Care Patients: A Comprehensive Analysis of Risk Factors in 314 Patients , 1995, The Annals of pharmacotherapy.

[20]  T. Boone,et al.  Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. , 1995, Blood.

[21]  C. Thompson.  Thrombopoietin , 1994, The Lancet.

[22]  Karlowicz Mg,et al.  Acute renal failure in the neonate. , 1992, Clinics in perinatology.

[23]  T. Yeh,et al.  The effect of low-dose dopamine infusion on cardiopulmonary and renal status in premature newborns with respiratory distress syndrome. , 1991, American journal of diseases of children.

[24]  R. Strauss,et al.  Guidelines for auditing pediatric blood transfusion practices. , 1991, American journal of diseases of children.

[25]  J. Kelton,et al.  Clinical impact of neonatal thrombocytopenia. , 1987, The Journal of pediatrics.

[26]  J. Kelton,et al.  Frequency and mechanism of neonatal thrombocytopenia. , 1986, The Journal of pediatrics.

[27]  V. Zanardo,et al.  Serum glutamic-oxaloacetic transaminase and glutamic-pyruvic transaminase activity in premature and full-term asphyxiated newborns. , 1985, Biology of the neonate.

[28]  L Neumann,et al.  Thrombocytopenia in the high-risk infant. , 1980, The Journal of pediatrics.

[29]  R. Jain,et al.  Acute renal failure in the neonate. , 1977, Pediatric clinics of North America.

[30]  D.,et al.  Regression Models and Life-Tables , 2022 .